T1	Participants 33 71	relapsing-remitting multiple sclerosis
T2	Participants 426 478	patients with relapsing-remitting multiple sclerosis
T3	Participants 569 653	Czech Republic, Germany, Hungary, India, Poland, Russia, Ukraine, Turkey, and the UK
T4	Participants 694 763	Patients aged 18-55 years with relapsing-remitting multiple sclerosis
T5	Participants 1293 1391	204 patients were assigned to receive placebo, 208 to daclizumab HYP 150 mg, and 209 to daclizumab
